---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Efficacy and safety"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Efficacy and safety. 1 evidence topic quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary/efficacy-and-safety"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Claseprubart Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary

MaGic is a phase 2, randomized, double-blind, placebo-controlled trial that enrolled 65 participants with AChR antibody-positive generalized myasthenia gravis, randomized 1:1:1 to claseprubart 300 mg or 600 mg subcutaneously every 2 weeks or placebo for 13 weeks, followed by a 52-week open-label extension. Its primary endpoint was safety; efficacy measures were secondary or exploratory, and P values were one-sided. Sixty-three of 65 participants completed the randomized period. At week 13, the mean change from baseline in MG-ADL was –4.6 with 300 mg and –5.4 with 600 mg, compared with –2.8 with placebo, placebo-adjusted differences of –1.8 (P=0.0113) and –2.6 (P=0.0006). The placebo-adjusted change in QMG was –2.4 (P=0.0144) and –2.5 (P=0.0111). MG-ADL minimal symptom expression was achieved by 37% (7/19) with 300 mg and 14% (3/22) with placebo (P=0.0550). The press release reported placebo-adjusted MGC changes of –5.6 and –5.5 (P=0.0008), while the later poster reported –4.1 and –4.3 (P=0.0023 and P=0.0016). Participants who continued claseprubart in the open-label extension maintained their improvement in MG-ADL, QMG, and MGC through 65 total weeks of treatment.

During the randomized period, infections occurred in 10 of 22 placebo participants (45.5%), 5 of 21 (23.8%) receiving 300 mg, and 6 of 22 (27.3%) receiving 600 mg. No participant receiving claseprubart had a treatment-related serious adverse event, and none discontinued for an adverse event; the only treatment-related serious infection occurred in the placebo arm. Injection site reactions occurred in 2 participants in each claseprubart arm, all mild to moderate. Among participants who were antinuclear antibody negative at baseline, 1 of 17 (5.9%) receiving 300 mg and 8 of 22 (36.4%) receiving 600 mg tested positive at a titer of at least 1:320 during the randomized period, and no symptoms indicative of autoimmune activation were reported. In the open-label extension (n=60), the poster table lists 1 participant (1.7%) under related serious adverse events, 1 (1.7%) under related serious infections, and 1 (1.7%) under discontinuation due to a related adverse event; its footnotes describe a participant with influenza who recovered and restarted claseprubart (not considered related by the sponsor) and a participant with arthritis. No meningococcal infections occurred, and one death from a cardiovascular event during the safety follow-up period was deemed unrelated to claseprubart.

These data are from a phase 2 trial with 21 to 22 participants per arm and are reported in company press releases and presentations and in congress posters and abstracts; no peer-reviewed full article reporting the trial was identified. The phase 3 EMERGE trial, comparing claseprubart 300 mg every 2 or 4 weeks with placebo on MG-ADL change at Week 17, began in June 2026 and has no results.

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm); [Peric et al. (2026e)](https://investor.dianthustx.com/static-files/2908a226-f34c-4b2e-9de3-69bd0bf53e0e); [Beydoun et al. (2026)](https://investor.dianthustx.com/static-files/d2e52c9c-ad1c-43ba-ac82-de6705cdf5eb); [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc); [ClinicalTrials.gov NCT06282159](https://clinicaltrials.gov/study/NCT06282159); [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
